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Infectious bursal disease (IBD) is a viral infection that affects young chicks. The IBD 
outbreaks in vaccinated chickens are frequently reported in Tanzania. The current study was 
conducted to determine the possible causes of vaccination failure focusing on knowledge, 
attitude and practices (KAPs) of vaccine sellers and poultry farmers, maternally derived 
antibodies (MDA), immunogenic potential of Virgo 7 vaccine and the phylogenetic 
relationship between the vaccine and the field strains. A cross-sectional study was performed 
to gather information on KAPs from 384 farmers and 20 veterinary outlets in Dar es Salaam. 
Results revealed inadequate knowledge of farmers in IBD management and breaches in the 
cold chain maintenance by vaccine sellers. A total of 60 chicks were experimentally 
vaccinated with Virgo 7 strain vaccine and titers of induced antibodies assessed. The vaccine 
induced adequate antibodies against IBDV, this confirming its immunogenic efficacy. 
Isolated nucleic acids from the vaccine and field strains were sequenced and result shows that 
field isolates are genetically different from the vaccine strains used in the country. The field 
isolates belong to the vvIBDV African types, while the vaccines belong to the vvIBDV 
European or classical virulent types. Putting together results from this study reveals multiple 
possible reasons which may contribute to vaccine failures. These include poor vaccine 
handling by farmers and vaccine seller and the genetic disparity between the field and 
vaccine strains. It is therefore recommended that veterinary regulatory authorities should 
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1.1  Background of the Problem 
The livestock industry is one of Tanzania’s agricultural sub-sectors contributing about 6.9% 
of the country’s gross domestic product as reported by National bureau of statistics [NBS] 
(2017). The livestock sector contributes to the national economy in terms of production of 
raw materials for industry, food production and creation of employment (Silva et al., 2017). 
Poultry as one of the classes of livestock is an emerging farming industry, which provides 
animal protein to the urban and peri-urban populations, source of income and creates 
employment opportunities (Pauw & Thurlow, 2010). However, the poultry industry is 
challenged by a lack of quality feeds, poor growth rate, prevalent diseases and poor 
sanitation. Major diseases that impede the development of poultry industry are newcastle 
disease, fowl pox, infectious coryza, infectious bursal disease (IBD), parasitism and 
nutritional related deficiencies (Musa et al., 2010). Vaccination is regarded to be the effective 
way to prevent most of these diseases, particularly infectious bursal disease, newcastle 
disease, infectious coryza and fowl pox that cause high morbidities and mortalities. Infectious 
bursal disease has been a great challenge to the poultry industry world-wide for a long time. 
However, the disease observed to be more challenging particularly for the past two decades 
following emergence of new pathotypes such as variant and very virulent strains (Sainsbury, 
2000). The IBD is one among the most important immunosuppressive diseases that creates 
serious economic problems for the poultry industry worldwide (Mutinda, 2016). The 
economic impacts of IBDV are diverse that include not only the direct losses due to 
morbidity and mortality, but also immunosuppression caused by this virus exacerbating 
infections with other pathogens (Kurukulasuriya, 2017). Thus, IBDV is one of the most 
important viral pathogens of commercial poultry. 
Infectious bursal disease is an acute and extremely contagious viral disease which affects 
growing chickens  between the age of three to six weeks (Swai et al., 2011). The IBD is 
caused by infectious bursal disease Virus (IBDV). The disease is also named as “Gumboro 




The IBD virus belongs to the family Birnaviridae under the genus Avibirnavirus (Brown, 
1986). It is non-enveloped and double-stranded RNA virus (Eterradossi et al., 2008). There 
are two IBDV serotypes reported worldwide namely, serotype I and II. However, it was 
reported that only serotype I contains pathogenic strain to chickens. The serotype I is further 
categorized as very virulent (VV), mild, intermediate, classical virulent and antigenic variants 
(Ching et al., 2007). Serotype II viruses are non-pathogenic to chickens, but mostly isolated 
from other birds like turkey and guinea fowl without manifesting clinical signs (Ismail et al., 
1988). 
The IBDV contains segment A and B which have been enclosed within non-enveloped 
icosahedral capsid. The segment A encodes viral proteins 2 (VP2), viral proteins 3 (VP3), 
viral proteins 4 (VP4) and viral proteins 5 (VP5) (Lejal et al., 2000). The VP2 contains 
essential neutralizing antigenic areas and produces a protective immune response. 
Furthermore, the majority of the amino acids changes between antigenically different IBDVs 
are occurred in the hyper-variable region of VP2 (Fahey et al., 1989). That is why VP2 is 
used for the IBDV identification and strain variation studies. The VP4 is a virus-encoded 
serine protease which is  responsible for the cleavage of the polyprotein (Birghan et al., 
2000). Viral protein 3 is dimeric in structure and it is considered to be a group-specific 
antigen because it is recognized by monoclonal antibodies directed against VP3 from strains 
of both serotype 1 and 2 (Becht et al., 1988). It is a multifunctional protein involved in 
determining the morphogenesis of the virus particle (Maraver et al., 2003). The nonstructural 
protein VP5 is involved in virus release and apoptosis (Liu & Vakharia, 2006). Segment B 
contains VP1, which is responsible for viral genome replication and mRNA synthesis 
(Jackwood et al., 1982). 
The main clinical signs manifested by diseased chickens are watery diarrhoea, 
immunosuppression hemorrhagic syndrome, depression, dehydration, inappetence, ruffled 
feathers, vent picking and reluctant to rise (OIE, 2000). The IBD virus affects B cells in 
immature stage and therefore induces immunosuppression (Meulemans, 2000). Since the 
chickens become immunosuppressed, they also develop a weak immune response when 
vaccinated against other diseases (Müller et al., 2012). Therefore,  infectious bursal disease is 





The prevention of this disease is mainly through vaccination and strictly bio-security 
measures (Müller et al., 2012). Adequate bio-security measures include restriction of farm 
visit and avoidance of mixing chickens from different flocks. This  is  very useful for disease 
prevention, especially before disease outbreak (Nespeca et al., 1997).  
There are two types of IBDV vaccines namely; live attenuated and inactivated vaccines. 
Proper timing for administration of live vaccines is extremely important, since when the 
vaccine is administered in early age the circulating maternally derived antibodies (MDA) 
tend to interfere with vaccine virus hence affect its performance (Müller et al., 2012). 
Inactivated vaccines observed to be very effective in vaccinating parent stocks before laying 
so that the protective antibodies can be transferred to their progenies. 
Maternally derived antibodies (MDA) are pathogen specific antibodies which vertically 
transferred from hen to the hatching progeny through the egg yolk (Cardenas-Garcia et al., 
2019). The MDA are absorbed from the yolk into the blood circulation of the chick and may 
work similarly to naturally induced antibody (Faulkner et al., 2013). The MDA can prevent 
clinical disease by passive vaccination for various pathogens in the chick (Faulkner et al., 
2013). Maternal derived antibodies against specific disease play an important role in 
protection of chicks against that disease before the development of active immunity (Ahmed 
& Akhter, 2003; Heller et al., 1990). Studies show that the level of MDA decrease with time 
and it reach a point where it become below the protective amount hence the chicks can be 
susceptible to the infection (Faulkner et al., 2013). On the other hand, chicks vaccinated 
while having high level of MDA against infectious bursal disease virus resulting in vaccine 
failure, due to of neutralization of the vaccine virus (Al-Natour et al., 2004; Naqi et al., 
1983). For that reason, it is very important to consider the half life of MDA in designing 
vaccination programs for chickens to minimize the cross reaction between circulating 
maternal antibodies and the vaccines (Gharaibeh & Mahmoud, 2013).  
For a long time, IBD has been reported to be one of the major hindrance factor for the poultry 
farming globally (Dey et al., 2019; Sainsbury, 2000). However, the disease has become more 
devastating especially in the last two decades after the appearance of very virulent and variant 
strains (Mutinda, 2016). Tanzania has also reported the existence of African and European 
vvIBDV strains (Kasanga et al., 2007). These strains affect both productivity and profitability 




Before 1980, IBDV strains were of low virulence and mortality and were effectively 
controlled through vaccination (Berg, 2000). However, IBD vaccine failures have been 
reported worldwide at the mid of 1980s (Berg, 2000). 
Vaccination failure could occur due to the fact that the local strains available in the fields are 
genetically different from vaccine strains (Chawinga, 2016), inappropriate administration of 
vaccines (Rosenberger et al., 1987), lack of vaccine potency (Ismail & Saif, 1991), 
interaction with maternally derived antibody (MDA) especially when vaccine is administered 
at early age, farmers’ inadequate knowledge about the disease and non-compliance with the 
vaccine’s cold chain specifications (Mbuko et al., 2010).  
The first report of infectious bursal disease in Tanzania came from Dar es Salaam and the 
Coast regions in 1988 (Kapaga et al., 1989). After that, the disease spread all over the country 
in poultry farming units that led to significant economic losses to farmers (Kasanga et al., 
2007). Even though chickens have been vaccinated against IBD, some farmers still reporting 
IBD outbreaks in both vaccinated and non-vaccinated chickens. This indicates an inefficiency 
or failure of vaccine used in the country (Kasanga et al., 2007). No evidence of research 
carried out to investigate the possible causes of vaccine failures, even though farmers 
reported IBD outbreak in vaccinated flocks. Therefore, the current study was conducted to 
explore the possible causes of vaccine failure including characterization and comparison of 
field IBDV strains and vaccine strains, assessment of immunogenic potential of the Virgo 7  
IBD vaccine commonly used in chicks in Tanzania and the knowledge, attitude and practices 
(KAPs) of poultry farmers towards managing IBD vaccines. 
1.2  Statement of the Problem 
Infectious bursal disease is among the most devastating disease in the poultry farming 
because of mortality and exposing chickens to be more susceptible to secondary infections 
(Kurukulasuriya, 2017). The disease is observed to be more severe in developing countries 
due to poor bio-security practices such as poor hygiene (Mohamed et al., 2014).  
The farmers in Tanzania use different types of IBDV vaccines and vaccination programs. 
However, IBD outbreaks are still reported in both vaccinated and non-vaccinated chickens 
(Kasanga et al., 2007). No evidence of research carried out to investigate the possible causes 




vaccinated chicken flocks. Therefore, the current study aimed to examine the possible causes 
of vaccination failure including characterization of field IBDV strains against vaccine strains, 
assessment of immunogenic potential of the Virgo 7 IBD vaccine commonly used in chicks 
in Tanzania and the KAPs of poultry farmers towards managing IBD vaccines.  
1.3  Rationale of the Study 
The farmers in Tanzania use different types of IBDV vaccines and vaccination programs to 
control IBD. However, IBD outbreaks are still reported in both vaccinated and non-
vaccinated chickens. This indicates an inefficiency of vaccines used in the country. 
Therefore, the current study aimed to examine the possible causes of vaccination failure in 
order to improve the poultry industry. Poultry farming provides animal protein to the urban 
and peri-urban populations, source of income and creates employment opportunities. 
1.4  Objectives 
1.4.1  Main Objective 
To assess the associated hindrance factors for the most commonly used infectious bursal 
disease vaccines for future improvement in poultry productivity in Tanzania. 
1.4.2 Specific Objectives 
(i) To assess the knowledge, attitude and practices of poultry farmers in managing IBD. 
(ii) To examine the decreasing trend of maternally derived antibodies against IBDV. 
(iii) To assess the immunogenic potential of the Virgo 7 intermediate hot strain IBD 
vaccines (VIR-114) in chickens. 
(iv) To characterize the phylogenetic relationship between field IBDV strains and 
currently used IBDV vaccine strains in Tanzania. 
1.5  Research Questions 
(i) What is the level of KAPs of poultry farmers in management of IBD? 




(iii) What is the level of antibody titer produced by (Virgo 7 intermediate hot strain IBD 
vaccines (VIR-114) in chickens? 
(iv) What is the phylogenetic relationship between field and imported IBD vaccines 
available in Tanzania? 
1.6  Significance of the Study 
This study pointed out the antigenic differences between circulating field IBDV strains and 
the current IBDV vaccine strains used in Tanzania. The study provides the information on the 
KAPs of poultry farmers and vaccine sellers on vaccine handling in Dar es Salaam region. 
Understanding of genetic disparity between the field and vaccine strains help in the 
development of a vaccine which will consider local IBDV isolates. The study findings will 
provide the baseline data on the KAPs of poultry farmers and vaccine sellers on vaccine 
handling in other regions within the country. 
1.7  Delineation of the Study 
The study was limited on investigation of possible causes for vaccination failure. It was based 
on assessing knowledge, attitude and practices of poultry farmers and vaccine sellers toward 
IBD vaccines management and immunogenic potential of Virgo 7 vaccine. Furthermore, the 
study involved assessment of phylogenetic relationship between field IBDV strains and 















2.1 Infectious Bursal Disease 
Infectious bursal disease (IBD) is an acute and highly contagious viral disease affecting the 
immune system of poultry in an immature stage (three to six weeks of age). The disease is 
caused by the infectious bursal disease virus (IBDV). The IBD virus belongs to the family 
Birnaviridae under the genus Avibirnavirus (Brown, 1986). It is non-enveloped RNA virus 
with double strands (Eterradossi et al., 2008). The disease is also termed as “Gumboro 
disease”,  because the first case occurred in Gumboro, Delaware, USA (Cosgrove, 1962).  
There are two IBDV serotypes reported worldwide which are serotype I and II. However, it 
was reported that only serotype I contain pathogenic strain to chickens. The serotype I is 
further categorized as very virulent (VV), mild, intermediate, classical virulent and antigenic 
variants (Ching et al., 2007). Serotype II viruses are non-pathogenic to chickens, but mostly 
isolated from other birds like turkey and guinea fowl without manifesting clinical signs 
(Ismail et al., 1988). 
The IBDV contains segment A and B which have been enclosed within non-enveloped 
icosahedral capsid. The segment A encodes viral proteins 2 (VP2), viral proteins 3 (VP3), 
viral proteins 4 (VP4) and viral proteins 5 (VP5) (Lejal et al., 2000). The VP2 contains 
essential neutralizing antigenic areas and produces a protective immune response. Also the 
majority of the amino acids changes between antigenically different IBDVs are occurred in 
the hyper-variable region of VP2 (Fahey et al., 1989). That is why VP2 is used for the IBDV 
identification and strain variation studies. Viral protein 4 is a virus-encoded serine protease 
which is  responsible for the cleavage of the polyprotein (Birghan et al., 2000). Viral protein 
3 is dimeric in structure and is considered to be a group-specific antigen because it is 
recognized by monoclonal antibodies directed against VP3 from strains of both serotype 1 
and 2 (Becht et al., 1988). It is a multifunctional protein involved in determining the 
morphogenesis and act as scaffolding element during the assembly of the virus particle 
(Maraver et al., 2003). The non-structural protein VP5 is involved in virus release and 
apoptosis (Liu & Vakharia, 2006). Segment B contains VP1 which is responsible for viral 




The infectious bursal disease is very devastating because of increased vulnerability of 
infected chickens to other diseases and affect vaccine efficiency (Saif, 1991). The disease is 
mainly targeting the immune system of the chickens (B lymphocyte). That is why it end up 
causing massive destruction of B cells in lymphoid organ and immunosuppression that 
increase disease susceptibility and secondary infection of infected birds such as Escherchia 
coli, salmonella and mycoplasma (Meulemans, 2000).  
Infectious bursal disease has become more devastating especially in the last two decades 
following the detection of very virulent and variant IBDV strains (Mutinda, 2016). Tanzania 
also has reported the existence of African and European vvIBDV strains (Kasanga et al., 
2007). These strains affect both productivity and profitability in the poultry industries all over 
the world (Sainsbury, 2000). Before 1980, IBDV strains were less virulent with low mortality 
and were effectively prevented through vaccination (Berg, 2000). However, IBD vaccine 
failures have been reported worldwide at the end of 1980s (Berg, 2000). Vaccination failure 
could occur due to the fact that the local strains available in the fields are genetically different 
from vaccine strains (Chawinga, 2016), inappropriate vaccine preparation and administration 
(Rosenberger et al., 1987), strength of vaccine virus (Ismail & Saif, 1991), interaction with 
maternally derived antibody (MDA) especially when vaccine is administered at early age and 
pathogenicity of circulating IBDV strains (Sainsbury, 2000). Farmers’ inadequate knowledge 
about the disease and non-compliance with the vaccine’s cold chain specifications might also 
cause failure of vaccination process (Mbuko et al., 2010). 
The first report of infectious bursal disease in Tanzania came from Dar es Salaam and the 
coast regions in 1988 (Kapaga et al., 1989). After that, the IBD spread all over the country in 
poultry farming units that led to significant economic losses to farmers. Even though 
chickens have been vaccinated against IBD, some farmers still reporting IBD outbreaks in 
both vaccinated and non-vaccinated chickens. This indicates an inefficiency of vaccines used 
in the country (Kasanga et al., 2007).  
2.2  Epidemiology 
2.2.1  Host Range 
Chickens are the only bird among avian species which develop IBD after being infected by 




viruses (McFerran et al., 1980), turkeys for serotype 2 (Ismail et al., 1988), guinea-fowl, 
phasianus colchicus and ostriches for serotype 2 viruses (Guittet et al., 1982). In addition, 
neutralizing IBD antibodies have been found in different types of undomesticated duck, 
goose, tern, puffin and penguin. This suggesting that wild birds may possibly play part in the 
epidemiology of IBD (Wilcox et al., 1983).  
2.2.2  Transmission and Pathogenesis 
The infectious bursal disease is an acute and extremely contagious viral disease that is 
transmitted primarily through the faecal-oral route as the virus is shed in the faeces. The 
incubation period for IBD varies between 2 to 4 days and the diseased chickens begin to shed 
the virus 24 hours after infection (Lawal et al., 2014). The IBD virus can live within the 
environment at a pH range of 2 to 12, in poultry houses for 122 days, in feed and water for 52 
days (Müller et al., 2012). The disease can be transmitted directly between bird to bird and 
indirectly through contaminated feeds, water, faeces, equipment, people’s clothing and shoes 
(Benton et al., 1967). Infectious bursal disease virus is very resistant to harsh condition and 
can survive for months in the poultry house environment. Elimination of the virus can be 
extremely difficult since the virus is resistant to several disinfectants (Benton et al., 1967). 
Following ingestion of the IBDV, phagocytic cells such as macrophages transferred it from 
the gut to the other tissues. The virus then reaches the bursal of fabricious via blood to 
destroy lymphoid follicles including B lymphocytes in the secondary lymphoid tissues such 
as GALT (gut-associated lymphoid tissue), CALT (conjunctiva), BALT (bronchial) and 
caecal tonsil (OIE, 2000). Necrosis and renal failure are the main cause of death for this 
disease (Muskett et al., 1985).  
Cells which produce IgM are the one which is targeted by the virus. Therefore, in the acute 
phase of the disease, the circulating IgM are decreased (Rodenberg et al., 1994). However 
circulating IgG level remains the same (Kim et al., 1999). The bursal is atrophied once the 
bursal follicles become depleted of B lymphocytes. Severe damage of lymphoid cells 
occurred following replication of viruses. Apoptosis of the neighbouring non-infected B cells 
causes destruction of the bursa morphology. At this period, a significant quantity of viral load 
can be found in other lymphoid organs such as caecal, tonsils and spleen (Tanimura & 
Sharma, 1997). The destruction of lymphocyte populations causes immunosuppression and 




2.3  Clinical Presentation  
Clinical presentation of IBD depends on the pathogenicity of the IBDV strains, age and breed 
of affected chickens (Mutinda, 2016). The most important clinical signs are in appetence, 
white watery diarrhoea, ruffling of feathers, vent picking, trembling, prostration and inability 
to move (Mohabe, 2012). The IBD can be presented in form of hyperacute, classical and 
immuno-suppressive.  
The classical virulent IBDV strains are the ones which cause classical form of IBD. The 
disease is presented by acute depression followed by typical signs and damages. The classical 
form of disease results in mortality of approximately 10 to 50%  (OIE, 2000). 
The hyper-acute form is caused by very virulent IBDV strains. The affected chickens show 
severe clinical signs which lead to high mortality rates. The hyper-acute form of disease 
cause mortality of approximately 50 to 84%  with typical signs and damage (Mutinda, 2016). 
Other studies reported that mortality caused by very virulent IBDV could vary between 40 to 
84% in specific pathogen free (SPF) chickens, 60% in layers, and 30% in broilers (Jackwood 
et al., 2009). 
The immunosuppressive form is mainly reported in United States. This form of disease is 
caused by IBDV strains with low pathogenicity and variant strains, such as the Delaware 
variant strains, which partially resistant to neutralization by circulating antibodies (Snyder, 
1990). Variant IBDVs induce little clinical signs and no mortality (Mohabe, 2012). 
2.4  Diagnosis 
Preliminary diagnosis of IBD involves consideration of flock’s history, clinical signs and 
findings at necropsy. Differential diagnoses with regard to clinical signs, include newcastle 
disease, mycotoxicosis, infectious bronchitis and inclusion body hepatitis. The disease may 
also be confused with chicken anaemia and Marek’s  in subclinical and immunosuppressive 
forms (Eterradossi et al., 2004). Nevertheles, these can easily be differentiated at necropsy. 
Confirmation of the disease can be done by detecting and characterizing specific IBD virus. 
For specific detection of IBD virus in affected tissues immunofluorescence tests, in-situ 
hybridization and based on labeled complementary cDNA sequence probe, are commonly 
used. Furthermore, viral RNA detection in infected chicken can be done by RT-PCR 




antibodies, this is done by using agar gel precipitation test (AGPT) and ELISA (Angani et al., 
2014). Furthermore, serological techniques are frequently used to identify the immunologic 
response in disease outbreak and evaluation of vaccine performance. 
2.4.1  Gross Lesions 
The extent of the lesions depends on the virulence of the IBD virus strains (Mutinda, 2016). 
Chickens which die from the acute condition exhibit dehydration of the subcutaneous fascia, 
inguinal, pectoral and thigh muscles (Cosgrove, 1962; Hirai et al., 1981). Haemorrhages 
appear in the pectoral and thigh muscles and occasionally appear on the mucosa at the 
proventriculus junction and plicae of the bursa (Huff et al., 2001). Kidneys enlarge and 
become pallor with an accumulation of urate in tubules (Cosgrove, 1962). Spleen observed to 
be enlarged, with tiny grey foci evenly distributed all over the parenchyma (Hirai et al., 
1981). 
Infection with classic viruses is demonstrated by increasing of the bursa dimension 
accompanied by inflammation. Once the inflammation subsides, the bursal is rapidly 
atrophied. Chickens that die early observed to double the size of the bursa because of 
oedema. The colour of the bursa changes to light yellow with striations. The bursa resume to 
its normal weight at day five. However, it continues to decrease in size from day eight 
onward and becomes one-third of its original weight (Hirai et al., 1981). The vvIBDV strains 
cause a massive reduction in thymic weight and massive damages in bone marrow, thymus, 
cecal tonsils and spleen. Nevertheless, the bursal damages are similar to other subtypes 
(Hasan et al., 2010). 
2.4.2  Histological Lesions 
Infectious bursal disease virus causes severe damage to lymphocytes hence causes damage of 
the bursa of fabricius and other lymphoid organs (Mahgoub, 2012). The death of B 
lymphocytes is easily diagnosed at day one of infection (Mahgoub, 2012). At day three of 
infection, an inflammatory reaction characterized by heterophils infiltration, oedema, 
congestion and haemorrhages appeared in the organ. At day four, the acute inflammatory 
responses decrease since necrotic materials have been cleared by phagocytic cells like 
macrophages. The highly pathogenic strains of IBDV causes severe thymocyte damage when 




and damage of lymphocytes have been observed in the caecal tonsils on day five following 
infection (Helmboldt & Garner, 1964). Damage of the liver tissues and fatty deterioration of 
hepatocytes have been reported in IBDV infection (Ma et al., 2013).  
2.5  Prevention and Control 
The prevention of this disease is mainly through vaccination and strictly bio-security 
measures (Müller et al., 2012). There are two main types of IBDV vaccines namely; live 
attenuated vaccine and inactivated vaccines. Proper timing for administration of live vaccines 
is extremely important because when the vaccine is administered in early age the circulating 
MDA tend to interfere with vaccine virus hence affect its performance (Müller et al., 2012). 
Inactivated vaccine is known to be very effective in vaccinating parent stocks before laying 
so that the protective antibodies can be transferred to their progenies. 
Furthermore, adequate bio-security measures including restriction of farm visit and avoidance 
of mixing chickens from different flocks are very useful for disease prevention, especially 
before disease outbreak. Implementation of bio-security measures after the disease outbreak 
will be useless since the virus can live in the chicken house and environment for a long 
period of time.  
2.5.1  Infectious Bursal Disease Vaccine 
(i)  Live Attenuated Vaccines 
This vaccine is developed by reducing the virulence of a pathogen, but still keeping its 
viability. The vaccines are mainly categorized into mild, intermediate and intermediate plus 
(hot) depending on the extent of attenuation (Rautenschlein et al., 2005).  
Mild vaccines are highly attenuated, breaking through very low levels of MDA. Therefore, 
they are no longer applicable in the commercial environment. The mild vaccine reported to 
cause limited bursal damage. 
Intermediate and intermediate plus (Hot) vaccines induce severe bursal lesions and could 
easily revert back to virulence resulting in disease and loss of production (Hair-Bejo et al., 
2004). Intermediate vaccine has few side effects, but limited efficacy against vvIBD in the 




powerful and aggressive action, but can damage the bursa, impairing the immune response 
and response to other vaccinations. Proper timing is critical in the administration of live 
vaccines to chicks due to interference with MDA (Müller et al., 2012). However, high 
parental immunity is the most important in protecting chicks from IBDV infection during the 
early age of life while the bursa is more prone to IBDV infection (Hitchner, 1976).  
Administration of this vaccine is generally through drinking water or spraying. When MDA 
is not detected in chickens, the mild vaccine is normally given at day one of age. If MDA is 
detected in early age, the vaccine is administered after the decline of MDA. However, the 
appropriate vaccination time is established by conducting serological test so as to establish 
the level of MDA. Currently, formulation of vaccines has been advanced in such a way that 
can be administered at day eighteen in hatchery through in-ovo route. Most of the live 
vaccines used in chicks are suitable for mass vaccinations that do not require an adjuvant and 
can replicate in the bird to stimulate both humoral and cell-mediated immunity (Müller et al., 
2012). 
(ii)  Inactivated Vaccine 
This vaccine consists of virus particle that has been grown in culture and then killed. The 
vaccine does not replicate in the bird. It is costly to produce and administer but, is very useful 
in parent flocks prior to laying to provide passive immunity to offspring via MDA (Haddad et 
al., 1997). The inactivated vaccines must have an antigenic content that is high enough to 
induce high immunity in parent flocks that can be passed to progeny at protective levels 
(Rosenberger et al., 1987). Infectious bursal disease vaccines have not been very successful 
in different parts of the world due to progressive changes in antigenicity and poor handling of 
the vaccines (Müller et al., 2012; Mutinda et al., 2014). However, vaccination still remains 
the best option in controlling IBDV in the field besides bio-security.  
2.6  Vaccination Failure 
Vaccination failure is described as the inability of the vaccinated chickens to produce 
sufficient amount of antibodies following administration of the vaccine (Abdullahi et al., 
2009). Vaccination failure could occur due to the fact that the local strains available in the 
fields are genetically different from vaccine strains, inappropriate vaccine preparation and 




is administered at early age, pathogenicity of circulating IBDV strains and non-compliance 
with the vaccine’s cold chain specifications. 
2.6.1  Non-usage of Local Antigen 
There are several serotypes of infectious bursal disease virus; these serotypes could be 
common in one region and different from other region. Usage of vaccine which contains IBD 
strains which are genetically different from field isolates may offer low protection or might 
not protect the chicks completely, hence result to vaccine failure (Mutinda et al., 2014). 
2.6.2  Presence of Maternally Derived Antibodies 
Establishment of the level of maternally derived antibody (MDA) before vaccination is 
extremely important. The high level of MDA’s provides protection at early age when the 
chicks are more likely to be affected by IBDV. However, high MDA titer may interfere with 
vaccine through neutralization (Sarachai et al., 2010) and thus recommended to vaccinate 
when the MDA titers waned out below protection level. 
2.6.3  Non-adherence to the Recommended Storage Temperature 
Once the vaccine has been formulated, the storage is very critical. The vaccines must be 
stored according to manufacturer recommendation. Live vaccines are always stored at 4 – 8 
C. Most of the vaccines used in chickens are heat intolerant. For this reason, adherence to 
the recommended storage temperature is crucial for best performance of vaccines. The cold 
chain breaks due to power cutoff, nonfunctional storage equipment, fluctuation of 
temperature during transportation and lack of standby generator are the commonly problems 
encountered in vaccine handling especially in developing countries (Hanjeet et al., 1996; 
Simba & Msamanga, 1994; Sudarshan et al., 1994; Thakker & Woods, 1992).  
2.6.4  Non-compliance to Vaccination Protocol 
Poor sanitation, lack of adherence to vaccination regimen, use of chlorinated water in vaccine 
reconstitution, may compromise the vaccine efficacy (Rosenberger et al., 1987). 
Furthermore, farmers’ inadequate knowledge about the disease and non-compliance with the 




2.7  Maternally Derived Antibodies 
Maternally derived antibodies (MDAs) are pathogen specific antibodies which vertically 
transferred from hen to the hatching progeny through the egg yolk (Cardenas-Garcia et al., 
2019). Maternally derived antibodies are absorbed from the yolk into the blood circulation of 
the chick and may work similarly to naturally induced antibody (Faulkner et al., 2013). The 
MDA can prevent clinical disease by passive vaccination for various pathogens in the chick 
and the MDA have a characteristic half-life similar to host antibodies before they naturally 
degrade in the chick (Faulkner et al., 2013). It is thought that MDAs bind to the target antigen 
preventing correct antigen presentation to B cells and initiation of a primary immune 
response. 
Maternal derived antibodies against specific disease play an important role in protection of 
chicks against that disease before the development of active immunity (Ahmed & Akhter, 
2003; Heller et al., 1990). Studies show that the level of MDA decrease with time and it 
reach a point where it become below the protective amount hence the chicks can be 
susceptible to the infection (Faulkner et al., 2013). On the other hand, chicks vaccinated 
while having high level of MDA against infectious bursal disease virus resulting in vaccine 
failure, due to neutralization of the vaccine virus (Al-Natour et al., 2004; Naqi et al., 1983). 
For that reason, it is very important to consider the half-life of MDA in designing vaccination 
programs for chickens to minimize the cross reaction between circulating maternal antibodies 
and the vaccines (Gharaibeh & Mahmoud, 2013). Several studies have been conducted with 
regard to duration of MDA. The study done by Skeeles (1979) and Wood (1981) showed that 
the half-life of MDA against IBDV varied between three to eight days. 
2.8  Enzyme Linked Immunosorbent Assay (ELISA) 
Enzyme-linked immunosorbent assay (ELISA) is a labeled immunoassay which is considered 
as the gold standard of immunoassays (Lequin, 2005). This immunological test is very 
sensitive and is used to detect and quantify substances such as antibodies, antigens, proteins, 
glycoproteins and hormones (Aydin, 2015). The detection of these products is accomplished 
by the complexing of antibodies and antigens to produce a measurable result. An antibody is 
a type of protein produced by an individual’s immune system. This protein type has specific 




events through the body’s immune system (Shah & Maghsoudlou, 2016). This interaction is 
utilized in ELISA test and allows for the identification of specific protein antibodies and 
antigens with only small amounts of a test sample. The ELISA test is used in the diagnosis of 
IBDV, newcastle disease and Brucellosis, among others. Antigen capture ELISA (Ac-
ELISA) had been used for the detection of IBDV antigens directly from infected tissues 
(Snyder et al., 1988). 
The ELISA test has been categorized into direct, indirect, sandwich, and competitive type. 
Enzyme-linked immunosorbent assays are performed in polystyrene plates, typically in 96 
well plates that are coated to bind protein very strongly. Depending on the ELISA type, 
testing requires a primary and/or secondary detection antibody, antigen, coating 
antibody/antigen, buffer, wash and substrate (Tiscione, 2018). The primary detection 
antibody is a specific antibody that only binds to the protein of interest, while a secondary 
detection antibody is a second enzyme-conjugated antibody that binds a primary antibody 
that is not enzyme-conjugated (Aydin, 2015). Generally, ELISA test involves coating (with 
either antigen or antibody), blocking, detection and final read. 
Detection is carried out by the addition of a substrate that can generate a color. There are 
many substrates available for use in ELISA detection. However, the most commonly used is 
horseradish peroxidase (HRP) and alkaline phosphatase (ALP). The substrate for HRP is 
hydrogen peroxide and results in a blue color change (Tiscione, 2018). Alkaline phosphatase 
measures the yellow color of nitrophenol after room temperature incubation periods of 15 to 









MATERIALS AND METHODS 
3.1  Ethical Approval 
The permission to carry out the study was obtained from the relevant bodies including 
Executive Directors of Ilala, Kinondoni, Temeke, Ubungo and Kigamboni municipals. The 
study was approved by the Northern Zone Health Research Ethics Committee (KNCHREC) 
and all the participants involved in the study were provided with a pre-informed consent form 
to express their willingness to participate on the study. 
3.2  Study Site and Population 
The study was conducted in Dar es Salaam region since it is the largest city in Tanzania. Dar 
es Salaam is located in the Eastern zone of Tanzania. The region is divided into five 
municipals namely; Ilala, Kinondoni, Temeke, Ubungo and Kigamboni.  It covers 1 393 Km
2
 
of land. The population census conducted in 2012 shows that Dar es Salaam has a human 
population of 4 364 541. The region was purposively selected since it is the largest center for 
commercial chicken production and a major consumer of poultry products in Tanzania 
(Mubito et al., 2014).  
3.3  Study design, Sampling and Sample Size 
The cross-sectional study design was employed to collect data which was used to assess 
knowledge, attitude and practices of selected commercial poultry farmers on IBD. The 
questionnaire was translated into “Swahili”, the national language that is understood by all 
Tanzanians. The questionnaire was pretested on a few poultry farmers from Ilala municipal to 
test the sequence of the questions as well as the estimated time for each questionnaire. Small 
modifications were made after the pilot study. Data from the pilot study was not used in the 
final analysis. 
A two-level multistage sampling technique was employed to obtain poultry farmers. The first 
stage involved the selection of study wards within five municipals. Wards were obtained by 
simple random sampling. The second stage involved obtaining commercial poultry farmers 




used as a sampling frame from which respondents were randomly selected.  A total of 384 
poultry farmers were randomly selected from different wards. The inclusion criteria were a 
poultry farmer who had 100 and above chickens. Three wards were randomly selected from 
each of the five municipals in Dar es Salaam. This made a total of 15 study wards. In each 
ward, a minimum of 25 poultry farmers were selected. 
To get the number of participants, a formula for cross-sectional studies of (Kish & Lisle, 
1965) was used. 
 
Where n = sample size, Z = level of confidence, P = baseline level of selected indicator and e 
= margin of error. 
The values were set at P = 0.5 (50%), since this was the first study to be done on assessment 
of KAPs of IBD in Tanzania, the maximum level of knowledge was assumed to be 50% , Z =  
1.96 (at 95% confidence interval) and e = 0.05. 
Purposive sampling technique was employed to obtain the number of veterinary shops 
included in the study. A total of 20 veterinary shops were purposively selected from different 
wards. The selected veterinary shops were the one that provided services to these farmers 
including selling vaccines. Purposive sampling technique was used in order to link the 
information between vaccine handling in the shop, vaccine handling from the shop to the 
farm and vaccine reconstitution and administration by the farmers. Therefore, all farmers 
interviewed in this study were asked to mention the place where they get IBD vaccines and 
all shops mentioned by farmers were included in the study. 
3.4  Data Collection Tools and Method 
A semi-structured questionnaire and checklist were used for a collection of data from all 
selected poultry farmers and vaccine sellers respectively. The personal interview was used to 
gather information from 384 poultry farmers and 20 veterinary outlets. The interviews 
focused on vaccination practices, vaccine handling from the shop, vaccine transportation and 
general IBD management. Data on the occurrence of IBD in vaccinated chickens and source 




compare with respondent’s answers and thus the respondents were cross-questioned to have 
the actual information. 
3.5  Examination of  Decreasing Trend of Maternally Derived Antibodies  
The experimental study started with preparation of chicken house. The chicken house was 
secured from Sokoine University of Agriculture (SUA). The selected room for the 
experiment were properly cleaned, disinfected with Virid
®
 and left for 2 weeks prior 
introduction of chicks to prevent any possible infections. The brooder house was made by 
using a clean ceiling board and the size of the brooder house was increased as the age of 
chick’s progress.  
Thirty (30) day old commercial broiler chicks were purchased from a poultry hatchery in 
Coast region and raised at SUA farm. These chicks were obtained from parent stocks who 
were vaccinated against IBD. Furthermore, chicks were given anticoccidial drug 
(Amprollium) at day 7 of age for 5 days and antibiotics for 5 days to prevent early infections. 
Chicks were raised in deep litter house made of rice husks. Electric bulbs with 200 W were 
installed in the brooder house to keep the room warm with the temperature ranged between 
35 to 40 C. Chicks were wing-tagged for individual identification. All chicks were raised in 
the environment with similar conditions for the whole period of study. Feed and water were 
supplied adilibitum. This trial was done as per the Tanzania Animal Welfare Act of 2008 
with efforts to minimize stress.  
The sample size of 30 chicks was proposed based on the previous study done by Mutinda 
(2016) with some adjustment. In this study, 20 chicks were proposed, however, in the current 
study, the number was adjusted to 30 chicks to compensate death if occurred. Blood was 
collected from wing vein of the chicks at specific intervals up to day 42. The chicken was 
handled by positioning it horizontally on its back, one hand hold the legs and the wing to 
support the chicken, the other hand was used to draw the blood. Sterile plastic disposable 
syringes of 2 mL and 29 gauges were used to collect blood. About 0.5 mL of blood was taken 














). Blood samples were left to clot at room temperature overnight. Each blood 




serum was harvested by using pasteur pipette and transferred into eppendorf tubes. All the 
sera were stored at -20 C until analysis. 
Serological analysis of the study samples was done by ELISA technique using indirect 
ELISA kits (ID Vet, France) as per manufacturer’s instructions. The ELISA kit reagents and 
serum samples that were stored at 2 – 8 C and at -20 C respectively were allowed to thaw at 
room temperature (25 – 27 C) prior to analysis. An aliquot (5 µL) of each sample were 
added to the microtitre plate. Then 245 µL of dilution buffer was added to all wells except to 
control well A1, B1, C1 and D1. That gave a 1:50 dilution of a serum sample to diluents in 
the dilution plate. After that, 384 µL of negative control was added to well A1 and B1 and 
384 µL of positive control were added to well C1 and D1 of the ID.vet test kit plate. 
Thereafter, 90 µL of dilution buffer was added to all wells except to control well A1, B1, C1 
and D1. Then 10 µL of the pre-diluted samples were added to each corresponding well of the 
ID.vet test kit plate. This gave 384 µL per well and final dilution of 1:500 in dilution buffer. 
The plate was covered and incubated for 30 minutes at room temperature. After 30 minutes 
the plate was emptied and washed three times with 300 µL of wash solution. The plate was 
then inverted and tapped firmly on absorbent paper. Then 384 µL of the conjugate was added 
to each well. The plate was covered and incubated for 30 minutes at room temperature. After 
30 minutes the plate was emptied and washed three times with 300 µL of wash solution. The 
plate was then inverted and tapped firmly on absorbent paper to dry. 384 µL of substrate 
solution was added to each well. The plate was covered and incubated for 15 minutes at room 
temperature. After that 384 µL of stop solution was added to each well to stop the reaction. 
The absorbance values were read and recorded at wavelength 450 nm using ELISA reader 
(Multiscan
TM
 FC Microplate Photometer). 
The antibody titer in chicken serum sample was calculated by referring to the positive 
control. That association was expressed as sample to positive ratio (S/P ratio). To confirm if 
the test results are valid the mean optical density (OD) value of the positive control should be 
greater than 0.250 and the ratio of the mean values of the positive and negative controls 
should be greater than 3.0. Interpretation of the results was done based on the S/P ratio and 
ELISA antibody titer. The result is positive if the S/P ratio is ˃ 0.3 or antibody titer ˃ 875 and 




3.6  Assessment of the immunogenicity of Virgo 7 strain vaccine 
The experimental study started with preparation of chicken house. Chicken house was 
secured from Sokoine University of Agriculture (SUA). The selected rooms for the 
experiment were properly cleaned, disinfected with Virid
®
 and left for 2 weeks prior 
introduction of chicks to prevent any possible infections. The brooder house was made by 
using a clean ceiling board and the size of the brooder house was increased as the age of 
chick’s progress.  
Sixty (60) day old commercial broiler chicks were purchased from a poultry hatchery in 
Coastal region and raised at SUA farm. These chicks were obtained from parent stocks who 
were vaccinated against IBD. Furthermore, chicks were given anticoccidial drug 
(Amprollium) at day 7 of age for 5 days and antibiotics for 5 days to prevent early infections. 
Chicks were raised in deep litter house made of rice husks. Electric bulbs with 200 W were 
installed in the brooder house to keep the room warm with the temperature ranged between 
35 to 40 C. Chicks were wing-tagged for individual identification and reared in isolated 
rooms after 14 days. All chicks were raised in the environment with similar conditions for the 
whole period of study. Feed and water were supplied adilibitum. This trial was done as per 
the Tanzania Animal Welfare Act of 2008 with efforts to minimize stress.  
The sample size of 60 chicks was proposed based on the previous study done by (Mutinda, 
2016) with some adjustment. In this study, 20 chicks were proposed per experimental group, 
but in the current study, the experimental group was adjusted to 30 chicks to compensate 
death if occurred. Regardless of the sex chicks were randomly assigned into two (2) groups of 
30 chicks. Group one was vaccinated and group two was not vaccinated that served as 
controls. 
Blood was collected from wing vein of the chicks at specific intervals up to day 42. The 
chicken was handled by positioning it horizontally on its back, one hand hold the legs and the 
wing to support the chicken, the other hand was used to draw the blood. Sterile plastic 
disposable syringes of 2 mL and 29 gauges were used to collect blood. About 0.5 mL of 














 of age to obtain the 
sera. Blood samples were left to clot at room temperature overnight. Each blood sample was 




harvested by using pasteur pipette and transferred into eppendorf tubes. All the sera were 
stored at -20 C until analysis. 
The vaccine used in this study was Virgo 7 strain (Biovac Limited, Israel). This is a live, an 
intermediate plus vaccine. Every dose contains about 10
2.5
 EID50. Virgo 7 strain vaccine was 
selected in this study for the reason that, the majority of poultry farmers in Tanzania use it for 
routine vaccination against IBDV. The vaccination requirements including handling, storage, 
schedule, reconstitution and administration were observed during the study. The vaccine was 
given to chicks at day 14 of age via drinking water as per manufacturer’s recommendation. 
Blood sampling was done at day 1, 14, 21, 28, 35 and 42 to monitor the antibody titres. 
About 0.5 mL of blood was collected per chick per sampling. 
Serological analysis of the study samples was done by ELISA technique using indirect 
ELISA kits (ID Vet, France) as per manufacturer’s instructions. The ELISA kit reagents and 
serum samples that were stored at 2 – 8 C and at -20 C respectively were allowed to thaw at 
room temperature prior to analysis. An aliquot (5 µL) of each sample were added to the 
microtitre plate. Then 245 µL of dilution buffer was added to all wells except to control well 
A1, B1, C1 and D1. That gave a 1:50 dilution of a serum sample to diluents in the dilution 
plate. After that, 384 µL of negative control was added to well A1 and B1 and 384 µL of 
positive control were added to well C1 and D1 of the ID.vet test kit plate. Thereafter, 90 µL 
of dilution buffer was added to all wells except to control well A1, B1, C1 and D1. Then 10 
µL of the pre-diluted samples were added to each corresponding well of the ID.vet test kit 
plate. This gave 384 µL per well and final dilution of 1:500 in dilution buffer. The plate was 
covered and incubated for 30 minutes at room temperature (25 – 27 C). After 30 minutes the 
plate was emptied and washed three times with 300 µL of wash solution. The plate was then 
inverted and tapped firmly on absorbent paper. Then 384 µL of the conjugate was added to 
each well. The plate was covered and incubated for 30 minutes at room temperature. After 30 
minutes the plate was emptied and washed 3 times with 300 µL of wash solution. The plate 
was inverted and tapped firmly on absorbent paper to dry. Then 384 µL of substrate solution 
was added to each well. The plate was covered and incubated for 15 minutes at room 
temperature. After that 384 µL of stop solution was added to each well to stop the reaction. 
The absorbance values were read and recorded at wavelength 450 nm using ELISA reader 
(Multiscan
TM




The antibody titer in chicken serum sample was calculated by referring to the positive 
control. That association was expressed as S/P ratio (Sample to Positive Ratio). To confirm if 
the test results are valid the mean optical density (OD) value of the positive control should be 
greater than 0.250 and the ratio of the mean values of the positive and negative controls 
should be greater than 3.0. Interpretation of the results was done based on the S/P ratio and 
ELISA antibody titer. The result is positive if the S/P ratio is ˃ 0.3 or antibody titer ˃ 875 and 
result was considered negative when the S/P ratio is ≤ 0.3 or antibody titer ≤ 875.  
3.7  Characterization of Field IBDV Strains and the Vaccine Strains Currently Used 
The IBDV samples used in this study were taken from the repository based at Sokoine 
University of Agriculture (SUA). The samples were obtained during IBD outbreaks in 
Morogoro (n = 2) and Dar es Salaam (n = 1) between 2016 and 2018. Two commercial live 
IBDV vaccines namely; Virgo 7 intermediate strain (Biovac Ltd, Israel) and Globivac- 
Intermediate plus strain (Globin, India) were purchased from the veterinary centres located in 
the study area.  
3.7.1  IBDV RNA Extraction 
The process was done by extracting viral RNA directly from the bursa samples obtained in 
the field and vaccines using RNeasy Min Extraction Kit (QIAGEN GmbH, Germany). The 
extraction was done as per the manufacturer’s instruction. Briefly, 460 µL of prepared lysis 
Buffer RLT was mixed with 460 µL of the viral sample in 1.5 micro centrifuge tube 
thereafter the mixture was incubated for 5 minutes at room temperature. Then 460 µL and 
70% ethanol was added to the mixture and mixed by vortexing for 15 seconds.  
The mixture was transferred into RNeasy spin column and centrifuged at full speed of 12 000 
rpm; 10 000 g for 15 seconds. The flow-through was discarded. The spin column was washed 
with 700 µL wash buffer RW1 and centrifuged for 10 seconds at 10 000 rpm. It was then 
washed with 500 µL wash buffer RPE and the flow-through was discarded.  
The washing was repeated with 500 µL using buffer RPE and centrifuged at full speed of 12 
000 rpm for 2 minutes to dry membrane. The old collection tube was discarded and the 
column was transferred to a new collection tube and centrifuged at maximum speed for 1 




water into a new 1.5 mL tube. The obtained viral RNA was stored in a freezer at -20 C. The 
tubes were clearly labeled and awaiting for reverse transcription process (cDNA synthesis). 
3.7.2  cDNA Synthesis (RevertAid First Strand cDNA) 
The complementary deoxyribonucleic acid (cDNA) strand was manufactured by using 
commercially available cDNA kit (RevertAid First Strand cDNA Synthesis Kit) 
manufactured by Thermo Scientific, Lithuania EU. The process contained the following 
reagents; Nuclease free water, extracted double-stranded RNA, Dimethyl sulfoxide (DMSO), 
reaction buffer, dNTPs, random hexamer primer, RNase inhibitor and reverse transcriptase 
enzyme (RevertAid RT). The process started by mixing 3 µL of each extracted dsRNA with 
1.5 µL of DMSO and incubated at 97 C for 5 minutes then immediately chilled on ice. The 
RT master mix which contains the reagent mentioned in Table 1 was added to the tube 
containing RNA-DMSO mixture to the final volume of 22.5 µL. The mixture was thoroughly 
mixed and the tubes were then sealed and centrifuged to settle down the contents and remove 
all bubbles. The sample mixture was then subjected into thermal cycler under the following 
conditions; 25
 
C for 10 minutes, 37
 
C for 120 minutes and 85
 
C for 5 minutes. The 
synthesized cDNA was kept at 4
 
C and used as a template for PCR. 
Table 1: Master Mix for Reverse Transcription 
No  Component Volume (µL) 
1 Reaction Buffer 4 
2 Ribolock 1 
3 Random Primer 1 
4 Revert Aid 1 
5 dNTP’s 2 
6 Nuclease free water 9 
  Total volume per  reaction  18 
 
3.7.3  Polymerase Chain Reaction 
Polymerase chain reaction (PCR) was conducted by targeting the VP2 hyper-variable regions 
(HVRs) of IBDV through gene-specific V1 forward primer (5-CCA GAG TCT ACA CCA 
TAA-3) and V2 reverse primer (3-CCT GTT GCC ACT CTT TCG TA) (Yamaguchi et al., 
1996). The process was done by using PCR readymade Kit (Bioneer Corporation, South 
Korea). Briefly, 12.5 µL of PCR premix, 2 µL of primers and 14 µL of nuclease-free water 




condition. The mixture was then loaded in the PCR machine for amplification. The 
amplification reaction involved initial denaturation at 97
 
C for 5 minutes, followed by 35 
thermal cycles of denaturation at 94
 
C for 30 seconds, annealing at 57
 
C for 30 seconds, 
elongation at 72
 
C for 30 seconds and final elongation step at 72
 
C for 5 minutes and hold at 
4
 
C overnight.   
3.7.4  Electrophoresis 
This process was done in order to visualize the obtained PCR products. The electrophoresis 
of the PCR product was done by first preparing the agarose gel. Briefly, the agarose gel was 
prepared by mixing 1.2 g of agarose powder with 384 mL of tris-borate-EDTA (TBE) reagent 
in a heat resistant conical flask. The mixture was then boiled using a hot plate with a 
magnetic stirrer to get a clear solution. The clear solution was left to cool at room 
temperature until it reaches a temperature of 50 C. Then, 3 µL of Gel red was added and 
swirled gently until the stain is clearly mixed. Casting tray was prepared by adding the 
appropriate combs on the tray and carefully pours the melted agarose solution on the casting 
tray. The tray with the gel solution was left for 45 minutes for the agarose gel to polymerize. 
The casting tray was placed in an electrophoretic chamber and TBE was added in an 
electrophoretic chamber until the gel was submerged. The combs were removed slowly and 
carefully to avoid breaking of the solidified gel. 
Five microliters of PCR products were mixed with 2 µL of loading dye. Thereafter, the 
mixture was loaded in the electrophoresis wells and stained with 3 µL Gel red. The reaction 
was carried out at 384 V for 45 minutes. Ultraviolet transilluminator was used for 
visualization of DNA bands. The gel picture was taken for further documentation. 
3.7.5  PCR Product Purification 
The obtained DNA amplicons were purified as per the GFX PCR purification protocol to get 
pure DNA. The DNA was purified from dNTPs, unused primers, salts and DNA polymerase 
which were used during PCR reaction. Briefly, the process involved mixing of 5 µL of 
captured buffer and 1 µL of PCR sample. Then a GFX spin column was introduced into 2 mL 
collection tube. The samples were added to the GFX column and centrifuged for 60 seconds. 
This is to ensure that the DNA binds into the column. The filtrate was discarded and the GFX 




buffer type 1 and centrifuged at 13 000 rpm for 60 seconds. After that, the GFX column was 
placed in a clean 1.5 mL micro centrifuge tube. To elute DNA, 20 µL elution buffer type 6 
was added to the centre of the GFX membrane. The column was left to stand for 1 minute 
and then centrifuged at 13 000 rpm for 1 minute.  
3.7.6  Cycle Sequence 
Purified DNA product was subjected to cycle sequencing by using Big Dye Terminator Kit. 
The process for one sample was done by mixing 3.5 µL of water, 2 µL of a buffer, 0.5 µL of 
Big Dye, 3 µL of primer and 1 µL of DNA. The required volume for six samples used in the 
study as indicated in (Table 2). The process was carried out under the following conditions; 
96
 
C for 1 minute in one cycle, (96
 
C for 10 seconds, 50
 
C for 0.05 seconds and 60
 
C for 4 
minutes) for 25 cycles and finally stored at 10
 
C till analysis. 
Table 2: Master Mix for Cycle Sequence 
No Component Volume (µL) × 1 Volume (µL) × 6 
1 Nuclease free water 3.5 21 
2 Buffer  2 12 
3 Big Dye 0.5 3 
4 Primer  3 18 
5 DNA 1 6 
 Total volume 10 60 
 
The product obtained from the cycle sequence was purified by ethanol precipitation. Ethanol 
precipitation was done by adding 5 µL 125 mM EDTA and 60 µL 384% ethanol to each 
purified DNA product. The mixture in the tube was vortexed and left in the darkroom for 15 
minutes and centrifuged at 13 000 rpm for 30 minutes. The supernatant was eliminated. Sixty 
microliters of 70% ethanol was added to the mixture and vortexed for 15 minutes followed by 
removal of all supernatant. Vacu-dry was done for 15 minutes in the dark and followed by 
addition of 20 µL Hi-Di formamide and then loaded in the sequencing machine.  
3.7.7  Nucleotide Sequencing and Phylogenetic Analysis 
Sequencing was done at the College of Veterinary Medicine and Biomedical Sciences, 




conducted as per (Sanger et al., 1977). The obtained nucleotide sequences were arranged and 
corrected to remove the primer binding part and the low-quality portion and retain the 
sequence quality of more than 95% by using Genius software, version 4.0.10. Confirmation 
of identity and homology of trimmed and edited sequence with the already uploaded 
sequences were done by using BLAST (Basic Local Alignment Search tool) on the NCBI 
website. Molecular evolutionary genetics analysis (MEGA) version 7 was used to perform 
the phylogenetic analysis of the study samples. The accuracy of the phylogenetic tree was 
calculated from the bootstrap values by using the Kimura two-parameter option with 3 840 
bootstrap replicates created by the neighbour-joining (NJ) method (Kimura, 1980). To build a 
phylogenetic tree, nucleotide sequences of the study samples (strain PDSM18, MMRG16, 
RMRG19, Virgo 7 strain and Globivac) and VP2 gene sequences from 32 IBDV strains with 
various genotypes that were taken from GenBank were used as shown in Fig. 1. The 
accession number for the study samples and the reference strains obtained from GenBank are 
shown in appendix 5.  
3.8  Statistical Analysis 
The data collected during the study were processed using Microsoft Excel 2019 and then 
imported into statistical package for social science (SPSS) version 20. Frequencies for all the 
variables were calculated, while means and standard deviations were computed for the 
continuous variables. Knowledge, attitude and practices were computed by adding the scores 
from the variables regarding the respective score. Chi-square test and simple linear regression 
were used to measure the association between several factors. P-value < 0.05 with 95% CI 
was considered to be significant.  
Calculation of the S/P ratio and the antibody titer was done by Microsoft Excel 2019. Data 
for serology were stored in Microsoft Excel 2019 before exported to SPSS for descriptive 
statistics. One-Way Analysis of Variance (ANOVA) was used to assess the differences in 
mean titers at each sampling time and the overall. 
The efficacy of the vaccine was assessed based on the results of serologic assays (titers post-
vaccination antibodies and the number of positive chickens). A Student t-test was used for 






RESULTS AND DISCUSSION 
4.1  Results 
4.1.1  Demographic Characteristics of Study Participants 
The socio-demographic characteristics of the study participants are presented in Table 3. A 
total of 384 poultry farmers in Dar es Salaam city were interviewed with more than half 
(66%) of the respondents being females who proportionally owned more flocks. The 
respondents had a mean age of 42 ± 9.3 years. Majority of the respondents (89%) were the 
owners of the project, the rest were the family member and attendants. Being the owner of 
their projects aided in the provision of right information regarding the control of the 
infectious bursal disease. The flock size varied between 170 and 4 000 chickens per 
household. More than half (53%) of the poultry farmers had between 5 to 8 years of poultry 
farming experience with the mean years of experience being 5.20 ± 3.14 years. 
About 71% of the respondents had secondary school education and above. Majority of the 
respondents were commercial poultry farmers (78%), followed by employees (13%) and 
others (9%). Of all the respondents interviewed, 73% observed to keep broilers, 21% layers 











Table 3: Demographic Characteristic of Study Participants 
Variable Frequency (n) Percentage (%) 
Gender     
Male 131 34 
Female 253 66 
Age   
20-25 20 5 
26-45 207 54 
46+ 157 41 
Level of education   
Primary 111 29 
Secondary 176 46 
Certificate 53 14 
Diploma 30 8 
Degree 15 3 
Marital status   
Married 326 85 
Unmarried 58 15 
Number of chickens   
170-300 42 11 
301-900 157 41 
901+ 185 48 
Types of chickens   
Broiler 280 73 
Layers 80 21 
Local 24 6 
Position of respondent   
Owner 341 89 
Attendant 34 9 
Family member 9 2 
Occupation   
Poultry keepers 299 78 
Employed 49 13 
Others 36 9 
 
4.1.2  Respondent’s Knowledge on IBD 
Majority of the respondent (91%) heard of infectious bursal disease (IBD). Results revealed 
that among 91% respondents who have heard of IBD previously, 40% heard from veterinary 
professionals, 31% and 29% of them had observed the disease at their homes and neighbours, 




of the causative agent. In addition, a small proportion (14%) of the respondents knew the IBD 
mode of transmission with clinical signs such as white watery diarrhoea, leg paralysis and 
sudden death frequently reported. 
Concerning sign and symptom of IBD, only 36% of respondents knew the clinical signs of 
IBD. Among the clinical signs mentioned, white watery diarrhoea (82%) was the frequently 
responded answer, followed by leg paralysis (15%) and sudden death (5%). The majority 
(91%) of the respondents knew that vaccine for IBD is available and the control of IBD is 
possible. Nearly two-thirds of the respondents (64%) knew that not all age groups of chicken 
can be affected by IBD (Table 4). 
Generally, the respondent appeared to have poor knowledge toward IBD on the causative 
agent, mode of transmission and symptoms. Furthermore, gender (p=0.024), education 
(p=0.014), flock size (p=0.021) and time for the keeping of chickens (p=0.01) had a 
significant influence on poultry keeper’s IBD knowledge. Age of respondents had no 
significant association to the knowledge on IBD since at t-value 1.188, df 382, P=0.238. 
Table 4: Knowledge of Respondents toward IBD in Dar es Salaam Region 
Variable Frequency (n) Percentage (%) 
Have you heard about IBD   
Yes 349          91 
No 35 9 
Where did you hear   
Veterinarian 140 40 
Happened on my farm 108 31 
Neighbors 101 29 
Causes of IBD   
I don’t know 227 65 
Virus 122 35 
Do you know the mode of transmission    
No 300 86 
Yes 49 14 
Do you know the clinical signs of IBD   
No 227 65 
Yes 122 35 
Signs and symptoms reported   
White watery diarrhea 286 82 
Leg paralysis 45 13 




4.1.3  Respondent’s Attitude Which Contribute to IBD Outbreaks 
All (100%) respondents agreed that maintaining a high level of bio-security measure help in 
preventing the spread of IBD. Majority (86%) of the respondents believe that IBD can be 
prevented by vaccination and 14% were neutral. A high proportion (89%) of respondents 
reported that proper vaccine handling including cold chain maintenance is important for 
vaccine effectiveness. About two-thirds (66%) of respondents did not know if the presence of 
disinfectants in water interferes with vaccine function (Table 5).  
Generally, the respondents had a positive attitude toward IBD with a mean score of 4.68 ± 
1.18 out of 6. On top of that, gender (p = 0.01), education (p = 0.03), flock size (p = 0.02) and 
time for the keeping of chickens (p = 0.01) have a significant influence on poultry keeper’s 
attitude toward IBD. 
Table 5: Attitude of the Respondent about IBD in Dar es Salaam Region 
Variable Frequency (n) Percentage (%) 
Good bio-security measures prevent IBD spread     
Agree  384 100 
Neutral 0 0 
Disagree  0 0 
IBD can be prevented by vaccination    
Agree 330 86 
Neutral 54 14 
Disagree 0 0 
Cold chain maintenance is important for vaccine  
Yes 341 89 
No 0 0 
I don’t know 43 11 
Presence of disinfectants in water interfere vaccine  
Function 
Yes 139 34 
No 0 0 
I don’t know 245 66 
Is IBD killer disease in chicken     
Agree 227 59 
Disagree 0 0 
Neutral 157 41 
Requested more information on IBD   
Yes 384 100 





4.1.4  Respondent’s Practices Which May Contribute to IBD Vaccines Failure 
Despite the fact that all respondents did routine cleaning, only 50% clean on a weekly basis, 
followed by 20% who did once per batch and 30% without a routine schedule for cleanness.  
Based on vaccine handling, all respondents admitted that vaccines are usually packed in a 
plastic bag with an ice pack for transport from veterinary shops to farms. Although 91% of 
respondents vaccinate against IBD, 19% experience IBD outbreaks (Table 6). The 90% of 
respondents who experienced IBD outbreaks after vaccination did not adhere to the entire 
recommended procedures for vaccine reconstitution, handling and bio-security measures. 
More than two-thirds (78%) of respondents vaccinate their chickens once using IBD vaccine 
and 22% vaccinate twice. It was also observed that water from different sources was used to 
reconstitute the IBD vaccine such as tap water (50%), well water (48%) and tap water mixed 
with skimmed milk (2%). Only 31% of the respondents placed a foot bath on the entrance of 




Table 6: Practices Related to IBD Management in Dar es Salaam Region 
Variable Frequency (n) Percentage 
(%) 
Disinfection of poultry house and equipment     
Yes 384 100 
No 0 0 
How often do you clean the chicken house, feeder and drinkers 
Every week 192 50 
Once per batch 77 20 
No specific schedule 115 30 
Do you have a foot bath on the entrance of the poultry house? 
Yes 119 31 
No 265 69 
Do you vaccinate your chicken   
Yes 349 91 
No 35 9 
Vaccination regimen for IBD?     
Once 272 78 
Twice 77 22 
Others  0 0 
Which water do you use in reconstituting the vaccine?   
Tap water 174 50 
Well water 167 48 
Tape water + milk 8 2 
Have you ever experience IBD after vaccinating the chickens 
Yes 70 20 
No 279 80 
 
4.1.5  Relationship between Knowledge, Attitude and Practices Scores 
The simple linear regression analysis revealed that there is an association between knowledge 
and practice (t = 2.404, p = 0.02), knowledge and attitude (t = 13.201, p < 0.01) and attitude 
and practice (t = 2.575, p = 0.01). The results confirm a relationship between knowledge, 
attitude and practices with regard to IBD management.  
4.1.6  Handling of a Vaccine in Veterinary Shops 
All the 20 veterinary shop owners who were interviewed reported packing vaccines in plastic 
bags with ice when they sell to their customers. Fourteen out of 20 shops observed to have 




training in handling of vaccines especially the maintenance of cold chain. Written procedures 
for vaccine handling and packaging into vaccine carriers was not available in all veterinary 
shops surveyed. There was neither temperature recording chart nor thermometer for 
monitoring the temperature in all the veterinary shops visited. 
4.1.7  Decreasing Trend of Maternally Derived Antibodies  
Based on ELISA results the mean value of maternally derived antibodies (MDA) decline 
rapidly from day 1 (2 931 ± 196.6) up to day 14 (1 297 ± 122.2) and thereafter progressive 
declining up to (196.5 ± 54.82) at day 42. The highest mean of MDA (2 931 ± 196.6) was 
recorded on day 1 of age. 
Significant differences (p = 0.00) in MDA titers at day 1, 14 and 42 were observed when 
compared by one-way analysis of variance (ANOVA) and this demonstrate that the MDA 
titers decreased from day to day and reach a level (196.5 ± 54.82) to which it cannot protect 
the chicks. 
 
Figure 1: Decaying Pattern of MDA with Age of Chickens 
4.1.8  Immunogenicity of Virgo 7 Strain Vaccine 
Following the administration of the Virgo 7 strain vaccine, the mean serum antibody titers in 
the vaccinated group started to increase which peaked on 3
rd 
week (day 35 of age). Compared 
to unvaccinated group, the mean serum antibody titers in the vaccinated group were 




control group progressively decreased and were at lowest levels on day 42 when the 
experiment was terminated. This was due to the diminishing of maternal antibodies.  
The variation of mean antibody titer between age group in vaccinated chickens was analyzed 
by one way ANOVA and found to be statistically significant (p = 0.0001). Furthermore, titers 
from vaccinated and non-vaccinated groups were compared using paired independent t-test 











Figure 2: Antibody Titer after Vaccination Compared to Unvaccinated Controls 
4.1.9  Extraction and Amplification of the IBDV Gene from the Field Samples and Vaccines 
The results show reliable amplicons IBDV VP2 HVR gene for 3 field samples (PDSM18, 
MMRG16 and RMRG19) and 2 imported IBDV vaccines (Virgo 7 strain and Globivac) after 
conducting PCR. 
4.1.10  BLAST Search Analysis of VP2 
After blasting the nucleotide sequences of the study samples, it was observed that the 
nucleotide sequences of 2 Tanzanian IBDV field samples (PDSM18 and MMRG16) were 
highly similar (94.68 - 96.33% nucleotide sequence identity) to a virus (LUSC47-2016) 
detected in Zambia 2016. Sample RMRG19 showed 99.53% nucleotide sequence identity 
with JG028/KEN/16 isolated in Kenya. Globivac vaccine showed 99.34% nucleotide 




100% nucleotide sequence identity with strain IBD10HLJ02 isolated in China, 713_Russia 
isolated in Russia, 213-048-2 isolated in Brazil, West Bengal/HBL-07-15-b isolated in India 
and V90/TW95 isolated in Taiwan. 
4.1.11  Phylogenetic Analysis 
Phylogenetic analysis using the HVR of the VP2 gene of the current IBDV samples and the 
representative strains from GenBank was performed to compare and verify the evolutionary 
lineage of the study samples. The phylogenetic tree revealed that the IBDV samples were 
separated into two main groups namely; Classical attenuated and very virulent (vv) viruses 
(Fig. 3). The very virulent (VV) IBDVs further divided into two major groups namely; VV1 
and VV2. The VV1 contains strains isolated from Africa including Tanzania, Zambia, Kenya 
and Nigeria which called vv IBDV African genotype, while VV2 contains strains isolated 
from various continents of the world including Africa, Asia America and Europe which form 
vvIBDV European genotype. The current field strains (RMRG19, PDSM18 and MMRG16) 
were grouped in the VV1 cluster while the imported Virgo 7 strain vaccine were grouped in 
VV2 and Globivac vaccine  was grouped in classical virulent type (Fig. 3).  
Phylogenetic tree based upon nucleotides of segment A showed that the field IBDV strain 
PDSM18 and MMRG16 are closely related (96% bootstrap value) with vvIBDV African type 
(LUSC47-2016). The field strain RMRG19 was more associated (66% bootstrap value) with 
both vvIBDV African types (JG028/KEN/16 and JG026/KEN/16). The imported Virgo 7 
strain vaccine was genetically closely related (97% bootstrap value) to the vvIBDV 
European/Asian type JG011/KEN/15, 213-048-2/2017, BD10HLJ02, 13_Russia-2017, 
V90/TW95 and   IBDV78/ABIC. The imported Globivac vaccine was genetically related to 
(100% bootstrap value) classical virulent (D78, 534_North_Carolina, 03-27950-dn and 
BD07IR). The sequence analyses indicated that the field strains were genetically different 





Figure 3: Phylogenetic Tree of 3 Fields IBDV Isolates, Reference Strains and Vaccines.  
Note: VV: Very virulent genotype, VV1: Very virulent African type; VV2: Very virulent 
European/Asian type; CV: Classical and antigenic variant genotype; Field isolate from 
Tanzania are in red; imported vaccines used in Tanzania are in green; reference strains 




4.2  Discussion 
Infectious bursal disease is very devastating disease in the poultry production as a result of 
mortality and exposing chickens to be more susceptible to secondary infections 
(Kurukulasuriya, 2017). The disease is more severe in Africa since the vaccines used are 
apparently not protective against emerging IBDV field strains (Mohamed et al., 2014) and 
inadequate bio-security measures. In Tanzania, some poultry farmers have encountered IBD 
outbreaks in both vaccinated and non vaccinated chickens, this indicating that there is a 
possibility of vaccine  inefficiency or failure (Kasanga et al., 2007). Therefore, the current 
study was performed to examine the possible causes of vaccination failure including 
assessment of immunogenic potential of the Virgo 7 strain IBD vaccine in chicks, 
knowledge, attitude and practices of poultry farmers and vaccine seller and phylogenetic 
relationship between circulating IBD virus strains in the fields and imported infectious bursal 
disease virus vaccine strains.  
To evaluate IBD knowledge of the poultry farmers, structured questionnaire was used. 
Results demonstrated that majority of poultry farmers had heard about infectious bursal 
disease in their locality. This demonstrates that IBD continue to be a most important threat of 
poultry production in the study area. Despite the majority of farmers having heard about the 
disease, knowledge concerning IBD is very low especially on causes, transmission and 
clinical signs similar to reports from other countries (Chawinga, 2016; Radostits et al., 2000). 
The knowledge gap identified in farmers with regard to causes, signs, and transmission 
against IBD is an indication of poor poultry extension services on IBD management. 
Therefore there is a need of strengthening poultry extension services and training to poultry 
farmers on disease management especially IBD. These extension services and training will 
improve farmer’s knowledge and subsequently lower IBD transmission rates. 
In contrast, the study conducted by Wahome (2018) reported a high level of knowledge and 
awareness about IBD among poultry keepers in Embu county, Kenya. The variation in 
awareness and knowledge on the clinical presentation of IBD, transmission and causes could 
be attributed to the endemic rate of IBD in the community, presence of veterinary services, 
formal training to poultry farmers and education through other media in Embu county, 




consulting veterinary officers whenever they see problems in their flocks and being exposed 
to the Medias where they get information on several diseases. 
Even though knowledge of IBD was low among poultry farmers, level of education found to 
influence farmers knowledge against IBD. Those with high level of education were observed 
to be somehow knowledgeable compared to those with low level of education. This could be 
due to the fact that educated farmers are more likely to understand disease management 
practices.  
Flock size and duration of keeping chickens also reported to influence farmer’s knowledge 
against IBD in this study. This could be due to the fact that, when farmers keep a large 
number of chickens they are more likely to consult their neighbours and veterinary personnel 
before vaccination and when there is disease outbreak due fear of loss. Furthermore, when 
farmers keep chickens for a long time they are most likely to encounter a number of diseases 
so they become aware of so many diseases. 
A structured questionnaire was also used to assess the practices of the poultry farmers and the 
results showed that 91% of respondents vaccinate their chickens against IBD. The findings 
were similar to the study conducted in Nigeria which showed that 84.1% of respondents 
vaccinated their birds (Bosha & Nongo, 2012). Furthermore, the study showed that 80% of 
famers who vaccinated their chickens against IBD did not experience disease outbreak. In 
this regard, it can be considered that the vaccines currently used in Tanzania might protect 
chickens against some field IBDV strains. The 20% vaccination failure observed in the study 
might be due to the consequences of violations of the prescribed good vaccine handling 
practices and administration demonstrated by some farmers which include poor sanitation, 
non-adherence to cold chain system, vaccine preparation and administration. Another 
explanation could be the IBDV strain affecting these farms is the mutated strain of IBDV 
isolated recently in this study (very virulent African type) which is genetically different from 
vaccine strains. Therefore, more education with regard to IBD management and vaccine 
handling and application should be provided to farmers so that we can reduce the cases of 
vaccination failure to zero. Furthermore, regular molecular monitoring of IBDV evolution is 
required in order to understand the dynamics of IBDV strains in Tanzania, since it is critical 




The majority of respondents reported that during vaccine reconstitution they use tap water 
that contains chlorine although IBD vaccine manufacturers recommended the use of chlorine-
free water or if doubtful add 2 g/L of skim milk. Addition of skimmed milk in water used for 
vaccination is very important as it help to prevent the harmful effect of chlorine and other 
disinfectants that might impinge on the efficiency of vaccine. Therefore, the practice of using 
potable water by most of the poultry farmers in the study area might be one of the causes for 
observed incidences of vaccination failure. This high rate of farmers using chlorinated water 
in vaccine reconstitution was also reported by Isegbe (2014). 
The present study also assessed the status of cold chain in veterinary outlets in Dar es Salaam 
region by using a checklist. The results showed that there was lack of functional thermometer 
in all veterinary shops surveyed. As per the vaccine logistic management guidelines, 
thermometer must be available in any vaccine storage center to record maximum and 
minimum temperature. This guarantee vaccine potency and the success of immunization, 
when it is not available at vaccine storage centers that means such centers do not monitor 
their refrigerator temperature and in that case the cold chain can easily be interrupted. The 
interruption of cold chain might affect the antigenicity of the vaccine hence result to 
vaccination failure. The finding is in agreement with (Azira et al., 2014; Simba & Msamanga, 
1994) who emphasized temperature monitoring in vaccine centers to ensure vaccines are of 
acceptable quality until administration to recipients. 
Another issue of serious concern was availability of power. Some of the outlets visited did 
not have backup generator in case of power outage. This give an indication that cold chain 
maintenance may be interrupted at some point and exposing the vaccines to unfavorable 
temperature. It should be noted that electricity or an alternative source of power is essential 
for cold chain maintenance as high temperature may cause death of viruses and affect the 
viability of antigenic material as reported by Bosha and Nongo (2012) and subsequently 
cause vaccine failure.  
The study revealed a high level of maternally derived antibodies (MDA) titers which were 
above the minimum (2 931 ± 196.6) protective level in the day-old chicks. This level was 
maintained up to day 7 and then decreased subsequently. High level of MDA noted in the 
present study implies that the parent stock was hyperimmunised and passed on a high level of 




protection of chickens at an early age when they are more susceptible to IBDV infection. On 
the other hand, high level of MDA need to be considered especially when implementing 
vaccination against IBD since high MDA titer at early age may interfere with vaccine through 
neutralization (Sarachai et al., 2010) and thus recommended to vaccinate when the MDA 
titers waned out below protection level. Based on the current study, chicks from breeder 
farms in Tanzania have higher MDA’s up to (2 931 ± 196.6) but declined rapidly to 1 297 ± 
122.2 after 14 days and continue to be detected in chickens up to day 42 with titer below 
protection level. With reference to the experimental study results it is recommended that 
vaccination will be successful if will be implemented after two weeks of age where MDA 
level will be below the protection level and less interference with live vaccines.  
An experimental study was conducted to evaluate the ability of commonly used IBDV 
vaccine (Virgo 7 intermediate hot strain IBDV vaccine) to induce antibodies against IBDV 
following vaccination of chickens. The results showed that, Virgo 7 vaccine was capable of 
producing antibodies against IBDV in vaccinated chickens. Based on the results obtained in 
the experimental study, it is recommended that vaccination will be successful if will be 
implemented after two weeks of age where MDA level will be below the protection level and 
less interference with live vaccines. However, farmers and other stakeholders should note that 
vaccination time depends on the source of chickens and the type of vaccines used. Different 
breeder farms have a different level of MDA (Hassan et al., 2018). Therefore, different 
vaccination schedule should be implemented. The current study has shown that, poultry 
farmers in Dar es Salaam use the same vaccination schedule regardless of the source and type 
of chicks. This might be one of the factors accounts for the incidences of IBD outbreaks in 
vaccinated chicken flocks. On the other hand, this study should be conducted on a wider scale 
so as to confirm the potency of other IBD vaccines being used in the country. Further study is 
also needed to examine the protective efficacy of this and other IBD vaccines being used in 
Tanzania. 
Phylogenetic analysis of three field strains and two imported vaccines strains has been 
conducted to assess their genetic relatedness. Phylogenetic study of the deduced nucleotide 
sequences of the three Tanzanian field strains showed that all samples belong to the 
pathogenic serotype-1, whereas subgenotype analysis revealed that the samples belong to the 
vvIBDV African genotypes, which include strains from the west, east and southern Africa. 




genotype while Globivac vaccine belonged to the classical strain. This indicates that, the 
vaccines used in the control of IBDV in Tanzania are genetically different from field isolate 
recently detected in Dar es Salaam and Morogoro and this may contribute to outbreaks in 
vaccinated flocks. This calls for further research on appropriate vaccines made using local 
IBD strains. 
Furthermore, other studies have demonstrated that vaccination of chicken using vaccine made 
by classical virulent IBDV strains to prevent the disease caused by very virulent IBDV strains 
might cause exchange of genes between the two virus and resulting to a natural reassortant 
virus as reported in China, Zambia and Argentina (Fernandes et al., 2012; Kasanga, 2015). In 
view of this, understanding the basis for evolutionary characteristics and genetic variation of 
field viruses could help veterinarians and researchers to design and develop new vaccines for 
controlling IBD, which cannot be controlled by current vaccines being used in the country. 
Generally, vaccine failures have been reported globally and are attributed to several factors. 
Under the current study the observed attributed factors for vaccination failure were poor 
sanitation, lack of adherence to vaccination regimen, use of chlorinated water in vaccine 
reconstitution, cold chain breaks due to frequent power outage, lack of standby generator and 
using vaccines with different strains from circulating field strain in Tanzania. Those factors 
may compromise the vaccine efficacy and vaccination process hence resulted to reported 
cases of IBD outbreak in vaccinated chicken’s flocks. 
4.3  Limitation of the Study 
There are limitations to our study that should not be overlooked when interpreting these 
findings. In establishing the efficacy of virgo 7 stains vaccine, antibody titer was used as the 
parameter for concluding efficacy of this vaccine. This has limitation since the antibodies 
produced might not be able to protect chickens against the field IBDV strains. Therefore, 
further studies are needed to investigate whether the induced antibodies by study vaccine are 








CONCLUSION AND RECOMMENDATIONS 
5.1 Conclusion  
The success of vaccination programme depends on various factors such as vaccine 
composition, route of administration, timing in administering vaccine, the ability of the 
chickens to produce protective antibodies after vaccination and the adherence of vaccine 
handlers to general good vaccine handling practices and manufacturer’s recommendation. In 
the current study, the knowledge of vaccine handling and administration was observed to be 
inadequate among both vaccine sellers and farmers. The present study pointed out that, there 
were a lot of breaches in the cold chain maintenance which may possibly jeopardize the 
efficacy of the vaccines and the overall quality of the vaccination services.  
The current study confirmed that maternal antibodies against IBDV are passively transferred 
to the progeny. Therefore, early vaccination may cause neutralization of vaccine virus by 
circulating MDA. The current study proposed vaccination using Virgo 7 strain vaccine to be 
at day 14
th
 of age as proposed by vaccine manufacturer since the vaccine was able to produce 
antibodies against IBDV in vaccinated chickens. However, further studies are needed to 
investigate whether the induced antibodies by study vaccine are protective against Tanzania 
IBDV strains.  
The current study discovered antigenic and genotypic differences between Tanzanian IBDV 
isolates and imported vaccine strains (Globivac and Virgo 7 strain). This study suggested 
considering of local virus isolates during vaccine development.  
5.2 Recommendations 
Poultry extension services should be strengthened to educate farmers and vaccine handlers 
(veterinary outlets) on the importance of observing all recommended vaccine protocol to 
minimize vaccine failure in the country.  
It is recommended that, it should be mandatory for vaccine manufacturers to include a leaflet 




Further research is recommended to address other factors that may influence time to 
vaccinate such as a source of chicks and type of vaccine and to confirm the potency of other 
IBD vaccines being used in the country apart from Virgo 7 strain vaccine. 
Further investigation is warranted to establish transmission dynamics, evolutionary 
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Appendix 1: Questionnaire to assess KAPs of poultry farmers on IBD in Dar es Salaam  
Socio-demographic information / Personal particulars of the respondent 
Respondent’s ID No.                            …………….. 
Interviewer initials                                [……………] 
Residence of respondent                     District....................          Ward................................
  
1.  How old are you now?................( Age in complete years). Year of birth 
……………….. 
2.  Sex of respondent       1. Male ……………        2. Female …………… 
3. What is your current marital status? 
1. Single (never married)                                        
2. Married 
4. Divorced/ separated  
5. Widowed                 
4.  What is the highest level of education you have completed? 
1. None     
2. Primary   
3. Secondary 
4. Certificates level 
5. Diploma level 
6. Degree level 
5. Position in the project: 1.Owner ................... 2.Family member...........  
            3. Attendant.............4.Others (Specify)..................................................... 
6. The number of chickens              …………………………………………  
7. What is your current main occupation? 
1. Commercial poultry keeper   ........... 
2. Employed                                 ............ 
3. Others  ...........  Specify.............................  
8. For how long have you kept chickens?........................ 
9. Types of chickens Kept 




 2. Layers 
 3. Local 
Knowledge of commercial poultry keepers on IBD 
10.  What major diseases of chickens do you encounter on your farm? Mention them in 




11.      Have you heard about IBD? (The researcher should clarify this question) 
                        Yes                                   No    
12.      If answered Yes, in question 10, where did you hear about this disease?  
          1. From veterinary doctors/Extension officers 
          2. Occurred on my farm 
          3. Occurred on my neighbour farm 
          4. Others, specify…………………………………………… 
13.     If answered Yes, in question 10, what clinical signs did the chickens presented? 
…………………………………………………………………………………………. 
…………………………………………………………………………………………… 
14.      Do you know how IBD is transmitted? 
            Yes                             No 
15.      If answered Yes, in question 13, how is it transmitted? 
………………………………………………………… 
…………………………………………………………. 
16.     If answered Yes, in question 13, how do you manage the disease? 
         Treating them    
         Vaccination            
          Leave them to die     
The attitude of commercial poultry keepers on IBD 
17.     Do you think your chicken can get IBD if you don’t observe bio-security measures?  
           Agree                          Neutral                        Disagree 
18.     Can IBD be prevented by vaccination? 
          Agree                         Neutral            Disagree 









   




         Yes                        No                  Don’t care 
20.    If answered Yes in question20, What special information on IBD would you like to 
know? 
         Basic knowledge                                                Prevention methods 
         Treatment                                                               Other        
21.    What are the best ways to get this information to you? 
          From veterinary doctors     
          Friends/family 
          Television 
          Radio 
          Other 
22.     Is the cold chain maintenance important for vaccine effectiveness? 
          1. Yes…..    2.  No.….     3. I don’t know …….. 
23.     Presence of disinfectants in water interfere vaccine function? 
          1. Yes ….    2. No ……   3. I don’t know 
24.     Is IBD a killer disease in chicken? 
          1. Agree ……. 2. Disagree   ….  3. Neutral ……….. 
Practices of commercial poultry keepers on IBD 
25.   Have you ever experience any difficulties on chicken keeping example, chicken death? 
          Yes                        No 
26.   What do you think could be the major cause of chicken death?  
         Diseases                      mention them ……………………………………………….. 
         No proper reasons             Others specify………………………. 
27.    Do you clean your chicken house and equipment? 
         1. Yes ………..  2. No ……………………. 
28.   How often do you clean the chicken house, feeder and drinkers? 
       …………………………………………………………………… 
29.   Do you have a foot bath on the entrance of the poultry house? 
        1. Yes ……….   2. No ………………. 
30.   Do you vaccinate your chicken? 
       Yes                        No 
31.    Vaccination regimen 




32.    If answered yes in question 26, Mention which diseases do you vaccinate?  
         ...........................................................................................................  
........................................................................................................... 
33.    Who vaccinates your chicken? If the answer is yes in question 26 
          Myself                                                  Livestock officer 
34.     Where do you get the vaccine? 
          Veterinary shop                           livestock officer   
35.     When you buy vaccine, do they provide information on storage and usage of the 
vaccine? 
           Yes                                               No 
36.     How do you handle the vaccine from the shop up to poultry house? 
          ………………………………………………………………………….. 
37.    When do you vaccinate after purchasing the vaccines? 
         Immediately               after some days           Others …………………… 
38.    Which water do you use in reconstituting the vaccine? 
         Tape water                       well water                     bottle water 
39.    Have you ever experience the disease after vaccinating the chickens? 
         Yes                                No 










Appendix 2: Checklist for Vaccine Storage and Handling 
Vaccine Storage and Handling Checklist 
 
Name of drug facility:  
SN People 
   
  
Yes No Comment 
1 All staff/personnel handling vaccines have been trained 
in the maintenance of the cold chain. 
  
   Equipment      
2 The refrigerator is situated away from heat sources   
 3 The refrigerator is situated away from direct sunlight   
 4 The refrigerator/cold room is operating normally                             
 5 There are no vaccines stored in the shelves of the door 
of the refrigerator 
  
 6 A map or guide to the location of vaccine is on the door 
of the refrigerator/cold chain 
  
 7 The electrical plugs are clearly marked "Refrigerator: 
Do not switch off" 
  
   Cold boxes, Vaccine carrier and coolers 
  
 
8 There are readily accessible written procedures for 
packing vaccine into cold boxes, vaccine carriers and/or 
coolers 
  
   Monitoring equipment      
9 A separate temperature recording chart/graph/sheet is 
used for each refrigerator 
  
 10 The current maximum and minimum temperatures have 
been recorded twice a day 
  
 11 The temperature record is kept close to the refrigerator   
 12 The daily temperature records are signed by the person 
taking the reading 
  
 13 Information about activities such as defrosting, etc., that 






14 There are procedures describing the action to be taken if 




Written vaccine storage and handling procedures are 
readily accessible to relevant staff                                                                          
  
 16 Were there any cold chain breaches?   
 17 What actions were taken in response to the cold chain breaches? 
  Alternative Vaccine storage 
  
  
18 A written procedure for alternative vaccine storage 
is readily accessible in the event of power failure 
or equipment breakdown 
  
 19 Alternative storage (eg Cooler or monitored 
refrigerator) is available for vaccine storage in the 
event of equipment failure 
  




      Information provided to vaccine customers 
  
 
21 Do the dispensers provide information on vaccine 
handling from the shop to the point of use? 
  
 22 Does the Information on how to reconstitute and 










Appendix 3: Informed Consent Form 





Greetings! My name is Rukia Saidi, I am a student doing Master’s in Global Health and 
Biomedical Sciences at Nelson Mandela African Institution Science and Technology (NM-
AIST). I am conducting a research on; knowledge, attitude and practices of commercial 
poultry farmers with reference to Infectious Bursal Disease transmission and management in 
Dar es Salaam region.  
Purpose of the study 
This study has the purpose of collecting information on knowledge, attitude and practices of 
commercial poultry farmers with reference to Infectious Bursal Disease transmission and 
management in Dar es Salaam region. You are being asked to participate in this study 
because you have particular knowledge and experiences that may be important to the study. 
What Participation Involves        
If you agree to participate in this study the following will occur: 
1. You will sit with a trained interviewer and answer questions about knowledge, 
attitude and practices of commercial poultry farmers with reference to Infectious 
Bursal Disease transmission and management. The interviewer will be recording your 
responses in the questionnaire. 
2. No identifying information will be collected from you during this interview, except 
your age, level of education, marital status and your current occupation. 





I assure you that all the information collected from you will be kept confidential. Only people 
working in this research study will have access to the information. We will be compiling a 
report, which will contain responses from several poultry farmers without any reference to 
individuals. We will not put your name or other identifying information on the records of the 
information you provide.  
Risks 
You will be asked questions about knowledge, attitude and practices of commercial poultry 
farmers with reference to Infectious Bursal Disease transmission and management. Some 
questions could potentially make you feel uncomfortable. You may refuse to answer any 
particular question and may stop the interview at any time. 
Rights to Withdraw and Alternatives 
Taking part in this study is completely your choice. If you choose not to participate in the 
study or if you decide to stop participating in the study you will not get any harm. You can 
stop participating in this study at any time, even if you have already given your consent. 
Refusal to participate or withdrawal from the study will not affect the quality of service to 
your chickens that are delivered by livestock officers.   
Benefits  
There will be no direct benefit to you, however, the information you provide will help to 
increase our understanding on knowledge, attitude and practices of commercial poultry 
farmers with reference to Infectious Bursal Disease transmission and management and 
prepare effective education interventions/programs to the general public on issues related to 
Infectious Bursal Disease transmission and management. The individual benefit may include 
advice on good animal husbandry practice that would make you maximize your profit.  
In Case of Injury 
We do not anticipate that any harm will occur to you or your family as a result of 
participation in this study. 
Who to contact 
If you have questions about this study, you should contact Studytudy Coordinator or the 
Principal Investigator, Rukia Saidi, Nelson Mandela African Institution Science and 
Technology (NM-AIST), P.O. Box 447, Arusha (Tel. no. 0717 210782 or 0767 210782 ). If 
you have questions about your rights as a participant, you may call Dr. Gabriel Mkilema 
Shirima who is the supervisor of this study (Tel. no. 0763 973003) 




I have been invited to take part in the study on knowledge, attitude and practices of 
commercial poultry farmers with reference to Infectious Bursal Disease transmission and 
management. I have read the foregoing information or it has been read to me and has 
understood. My questions have been answered to my satisfaction. I agree to participate in this 
study. 
Signature 
Do you agree?  
Participant Agrees [__]   
Participant disagree [__] 
 
Signature (or thumbprint) of participant   ……………………………………. 
Signature of witness (if the participant cannot read) ……………………………. 
Signature of research assistant ……………………………………………….. 













Appendix 4: Infectious Bursal Disease Strains used in the Phylogenetic Tree 
Virus strain Accession no Origin Genotype 
BJ836 AF413069.1 China Classical 
IBD071R  KT633995.1 Iran Classical 
534-North-Carolina MF142546.1 USA Classical 
IBDV76/NVR1 JX424075.1 Nigeria Classical 
D78 EU162087.1 USA Classical 
03-27950-dn EF138988.1 Canada Classical 
GBF-1  D16828.1 Japan Classical 
JG011/KEN/15 KY407590.1 Kenya VV-EU Type 
213-048-2 KY556581.1 Brazil VV-EU Type 
713-Russia MF142562.1 Russia VV-EU Type 
KM523629.1 IBD10HLJ02 China VV-EU Type 
West Bengal/HBL-07-15-b KT630855.1 India VV-EU Type 
V90/TW95 JQ315162.1 Taiwan VV-EU Type 
IBDV78/ABIC vaccine IBD10HLJ02 Russia VV-EU Type 
UK661 KT630855.1 China VV-EU Type 
D6948 JQ315162.1 India VV-EU Type 
KMRG-40 AB200982.1 Tanzania VV-A Type 
KARS-53 AB200984.1 Tanzania VV-A Type 
KMZA-78 AB200985.1 Tanzania VV-A Type 
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